Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 9:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Bacteriophage Treatment Clear all
Completed Phase 1Phase 2 Interventional Results available

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

NCT04596319
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas, Lung Infection, Lung Infection Pseudomonal
Interventions
AP-PA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Los Angeles, California • Tampa, Florida • Boise, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 1Phase 2 Interventional

Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

NCT05010577
View directory record Official record
Conditions
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis
Interventions
BX004-A, Placebo
Drug
Lead sponsor
BiomX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 14, 2026, 9:15 AM EDT
Terminated Phase 2 Interventional

Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis

NCT05177107
View directory record Official record
Conditions
Osteomyelitis, Diabetic Foot Osteomyelitis
Interventions
Bacteriophage Therapy, Placebo
Biological · Other
Lead sponsor
Adaptive Phage Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
Tuscon, Arizona • Fairfield, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 14, 2026, 9:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients

NCT06409819
View directory record Official record
Conditions
Urinary Tract Infection, Recurrent
Interventions
phage therapy, control
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 14, 2026, 9:15 AM EDT
Recruiting Not applicable Interventional

Project 4: ACHIEVE PATHFINDER

NCT06070428
View directory record Official record
Conditions
Heart Failure
Interventions
PAC provision at hospital discharge, Control non-intervention; PAC without filter
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 1 Interventional

A Prospective, Randomized, Double-Blind Controlled Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers

NCT00663091
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
Bacteriophage, WPP-201 Bacteriophage, Bacteriophages
Drug
Lead sponsor
Southwest Regional Wound Care Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2011 · Synced Sep 14, 2026, 9:15 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Photodegraded Edible Food Dyes

NCT04708704
View directory record Official record
Conditions
Thyroid; Functional Disturbance
Interventions
Erythrosine, prepared in drinking water (0.69 mg/kg bw/day), SODIS-treated erythrosine, prepared in drinking water (0.69 mg/kg bw/day), Iodine, prepared in drinking water 0.075 mg/kg bw/day)
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Not applicable Interventional

Ritual Synbiotic+, a Dietary Supplement Designed to Impact Gastrointestinal Health, Mood, and Behavior in Women

NCT06834984
View directory record Official record
Conditions
Gastrointestinal Disease Symptoms
Interventions
Prebiotic, probiotic, postbiotic combination, Placebo
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 14, 2026, 9:15 AM EDT
Recruiting Phase 2 Interventional

Study With Phage for CF Subjects With Pseudomonas Lung Infection

NCT06998043
View directory record Official record
Conditions
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
Interventions
BX004, Placebo
Biological · Other
Lead sponsor
BiomX Ltd
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 14, 2026, 9:15 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis

NCT05182749
View directory record Official record
Conditions
Shigellosis
Interventions
bacteriophage, Placebo
Biological · Other
Lead sponsor
Intralytix, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Sep 14, 2026, 9:15 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease

NCT03808103
View directory record Official record
Conditions
Crohn Disease
Interventions
Placebo, Bacteriophage preparation
Biological
Lead sponsor
Intralytix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
2
States / cities
Lutherville, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)

NCT04684641
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Standard Dose YPT-01, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 1 Interventional

Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems

NCT00006066
View directory record Official record
Conditions
HIV Infections
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Diphtheria and Tetanus Toxoids Adsorbed, Tetanus and Diphtheria Toxoids Adsorbed, Bacteriophage phi X 174, Aldesleukin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
13
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 14, 2026, 9:15 AM EDT
Withdrawn Phase 2 Interventional

Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)

NCT05269134
View directory record Official record
Conditions
Prosthetic Joint Infection
Interventions
Bacteriophage, Placebo
Drug
Lead sponsor
Adaptive Phage Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
San Diego, California • Hartford, Connecticut • Idaho Falls, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

NCT05184764
View directory record Official record
Conditions
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions
AP-SA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 14, 2026, 9:15 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Bacteriophage Therapy in Patients With Prosthetic Joint Infections

NCT04787250
View directory record Official record
Conditions
Prosthetic Joint Infection
Interventions
Phage Therapy, Two-Stage Exchange Arthroplasty
Biological · Procedure
Lead sponsor
Adaptive Phage Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy Adults

NCT04737876
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BX002-A, Placebo
Biological · Other
Lead sponsor
BiomX, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Sep 14, 2026, 9:15 AM EDT
Recruiting Phase 1 Interventional

Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria

NCT06559618
View directory record Official record
Conditions
Bacteriuria, Spinal Cord Injuries, Asymptomatic Bacteriuria, Escherichia Coli
Interventions
Phage Therapy, Placebo
Drug · Other
Lead sponsor
Barbara Trautner
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli

NCT04191148
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
LBP-EC01, Placebo
Drug
Lead sponsor
Locus Biosciences
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Anniston, Alabama • Irvine, California • Doral, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

NCT05616221
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Interventions
AP-PA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Farmington, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 14, 2026, 9:15 AM EDT
Recruiting Phase 1 Interventional

Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection

NCT07275905
View directory record Official record
Conditions
Cystic Fibrosis (CF), Achromobacter Infection
Interventions
AchromoPhage
Biological
Lead sponsor
Ghady Haidar
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
San Diego, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

NCT05453578
View directory record Official record
Conditions
Bacterial Disease Carrier, Cystic Fibrosis
Interventions
Placebo, WRAIR-PAM-CF1
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
19
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 14, 2026, 9:15 AM EDT
Recruiting Not applicable Interventional

Multiomic Diagnostics in Youth With Psychosis

NCT05457140
View directory record Official record
Conditions
Psychosis
Interventions
Genetic: Genomic sequencing and molecular diagnostic results, if any., Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)
Genetic · Diagnostic Test
Lead sponsor
Rady Pediatric Genomics & Systems Medicine Institute
Other
Eligibility
7 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 2 Interventional

Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection

NCT05948592
View directory record Official record
Conditions
Diabetic Foot Infection
Interventions
TP-102, Placebo
Biological · Other
Lead sponsor
Technophage, SA
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Webster, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 14, 2026, 9:15 AM EDT